Comparison Recurrence Rate of Amniotic Membrane Without Mitomycin C Versus Amniotic Membrane with Mitomycin C for Treatment Pterygium in Banpong Hospital
Keywords:
pterygium, amniotic membrane transplantation, mitomycin C, recurrence, complicationAbstract
Objective: The primary objective of this study was to examine the recurrence rate of pterygium excision treatment using amniotic membrane transplantation (AMT) compared to amniotic membrane transplantation with mitomycin C (AMT with MMC) in Banpong Hospital. The secondary objective was to examine the complications that occurred from these two surgical techniques for statistical difference and identify the most effective approach for treatment of pterygium.
Methods: This retrospective descriptive study evaluated patients with pterygium excision using the amniotic membrane transplantation with or without mitomycin C in Banpong Hospital from March 1, 2023 to February 28, 2024. The study sample size consisted of 55 patients (25 with mitomycin C and 30 without mitomycin C). Data points included recurrence rate and associated treatment complications occurring at 1, 3, and 6 months post-operative. The data were analyzed by using statistical package and presented by frequency, mean, and standard deviation. Fisher’s exact test was used to analyze significant difference between the two groups.
Results: Baseline demographic and clinical characteristics were similar between groups. There was no statistically significant difference in the recurrence rate at 1, 3, and 6 month post-operative after pterygium treatment with AMT and AMT with MMC (p-value > .99, .112, and .092 respectively). Two cases of corneal dellen were observed at 1 month in the AMT-alone group, both resolving by the 3- and 6-month follow-ups. No statistically significant differences in postoperative complications were identified between the two groups.
Conclusion: Pterygium excision with AMT and AMT combined with MMC demonstrated no statistically significant differences in recurrence rates or postoperative complications. Both surgical approaches appeared to have comparable safety and efficacy profiles. No serious complications were observed with the use of MMC, such as scleral perforation or intraocular infection.
References
Hilgers JH. Pterygium: its incidence, heredity and etiology. Am J Ophthalmol. 1960;50:635–44. doi: 10.1016/0002-9394(60)90245-2.
Liu L, Wu J, Geng J, Yuan Z, Huang D. Geographical prevalence and risk factors for pterygium: a systematic review and meta-analysis. BMJ Open. 2013;3(11):e003787. doi: 10.1136/bmjopen-2013-003787.
Pyo EY, Mun GH, Yoon KC. The prevalence and risk factors for pterygium in South Korea: the Korea National Health and Nutrition Examination Survey 2009–2010. Epidemiol Health. 2016;38:e2016015. doi:10.4178/epih.e2016015.
Chaidaroon W, Vichakutakul W. Prevalence and associated factors for pterygium at a tertiary referral center in Northern Thailand. Thai J Ophthalmol. 2016;30(2):95–100.
สุพรรณ ศรีธรรมมา. โรคต้อเนื้อพบมากในวัยกลางคน. วารสารกรมการแพทย์. 2558;21(2):7–8.
Tan DT, Chee SP, Dear KB, Lim AS. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol. 1997;115(10):1235–40. doi: 10.1001/archopht.1997.0110016 0405001.
ประกิต คล้ายสุบรรณ, ศิริรัตน์ โพธิ์ศรีทอง. ผลการใช้งานยาหยอดตามัยโตมัยซิน ซี ระดับความเข้มข้นต่ำในการป้องกันการกลับมาเป็นซ้ำภายหลังการลอกต้อเนื้อในโรงพยาบาลเจ้าพระยายมราช สุพรรณบุรี. วารสารโรงพยาบาลสกลนคร. 2557;17(1):26–35.
Song YW, Yu AH, Cai XJ. Effectiveness of amniotic membrane transplantation combined with mitomycin C in the treatment of pterygium: a meta-analysis. Int J Ophthalmol. 2010;3(4):352–5. doi: 10.3980/j.issn.2222-3959.2010.04.18
Martins TGDS, Costa ALFDA, Alves MR, Chammas R, Schor P. Mitomycin C in pterygium treatment. Int J Ophthalmol. 2016;9(3):465–8. doi: 10.18240/ijo.2016.03.25
Bernard R. Fundamentals of biostatistics. 5th ed. Pacific Grove, CA: Duxbury; 2000.
El-Shahed AF, El-Shahed FS, Yousef WA, El-Shahed RF. A comparative study between amniotic membrane transplantation and topical mitomycin-C in recurrent pterygium management. Delta J Ophthalmol. 2024;25(2):82–7. doi:10.4103/djo.djo68_23.
Ittipanichpong P. Pterygium surgery with superior conjunctival autograft in Sawanpracharak Hospital. Sawanpracharak Med J. 2012;9(1):15–24.
Jampel HD. Effect of brief exposure to mitomycin C on viability and proliferation of cultured human Tenon’s capsule fibroblasts. Ophthalmology. 1992;99(9):1471–6. doi:10.1016/s0161-6420(92)31781–6.
Lee HJ, Kim YJ. Comparison of surgical methods and the use of mitomycin-C for the treatment of recurrent pterygium. Invest Ophthalmol Vis Sci. 2016;57(12):3539.
Razmjoo H, Kashfi SA, Mirmohammadkhani M, Pourazizi M. Recurrence rate and clinical outcome of amniotic membrane transplantation combined with mitomycin C in pterygium surgery: two-year follow-up. J Res Pharm Pract. 2020;9(1):10–5. doi: 10.4103/jrpp.JRPP_19_127.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ลิขสิทธิ์บทความเป็นของผู้เขียนบทความ แต่หากผลงานของท่านได้รับการพิจารณาตีพิมพ์ลงวารสารแพทย์เขต 4-5 จะคงไว้ซึ่งสิทธิ์ในการตีพิมพ์ครั้งแรกด้วยเหตุที่บทความจะปรากฎในวารสารที่เข้าถึงได้ จึงอนุญาตให้นำบทความในวารสารไปใช้ประโยชน์ได้ในเชิงวิชาการโดยจำเป็นต้องมีการอ้างอิงถึงชื่อวารสารอย่างถูกต้อง แต่ไม่อนุญาตให้นำไปใช้ในเชิงพาณิชย์
